Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile

G. Ackermann, Y. J. Tang-Feldman, R. Schaumann, J. P. Henderson, A. C. Rodloff, Jr Silva, Stuart H Cohen

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective. Moxifloxacin is characterized by high activity against Gram-positive cocci and some Gram-positive and -negative anaerobes, including Clostridium difficile. This study investigates the role of prior quinolone use in relation to patterns of susceptibility of C. difficile to moxifloxacin. Methods. Sixty-three clinical isolates of C. difficile were investigated for toxigenicity, susceptibility to moxifloxacin, and mutations in the DNA gyrase gene. The medical histories for 50 of these patients were available and used to identify previous fluoroquinolone use. Results. Thirty-three (52.4%) strains showed resistance to moxifloxacin (MICs ≥ 16 mg/L). All moxifloxacin-resistant strains harbored a mutation at amino acid codon Ser-83 of gyrA. Forty-five isolates (71.4%) were toxigenic; all moxifloxacin-resistant strains were in this group. Resistance to moxifloxacin was associated with prior use of fluoroquinolones (P-value 0.009, chi-square). Conclusions. Although the use of moxifloxacin to treat C. difficile-associated diarrhea is not likely to be common, these data show a relationship between antecedent fluoroquinolone use and resistance to moxifloxacin in C. difficile isolates, and raise questions regarding selection pressure for resistance placed on colonizing bacteria exposed to fluoroquinolones. Mutations in gyrA are involved in moxifloxacin resistance.

Original languageEnglish (US)
Pages (from-to)526-530
Number of pages5
JournalClinical Microbiology and Infection
Volume9
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Clostridium difficile
Fluoroquinolones
Mutation
moxifloxacin
DNA Gyrase
Gram-Positive Cocci
Quinolones
Codon
Diarrhea
Bacteria
Amino Acids
Pressure

Keywords

  • Clostridium difficile
  • Moxifloxacin
  • Resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. / Ackermann, G.; Tang-Feldman, Y. J.; Schaumann, R.; Henderson, J. P.; Rodloff, A. C.; Silva, Jr; Cohen, Stuart H.

In: Clinical Microbiology and Infection, Vol. 9, No. 6, 01.06.2003, p. 526-530.

Research output: Contribution to journalArticle

Ackermann, G. ; Tang-Feldman, Y. J. ; Schaumann, R. ; Henderson, J. P. ; Rodloff, A. C. ; Silva, Jr ; Cohen, Stuart H. / Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. In: Clinical Microbiology and Infection. 2003 ; Vol. 9, No. 6. pp. 526-530.
@article{30e40716ec064c319e3e2ccbc62f923b,
title = "Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile",
abstract = "Objective. Moxifloxacin is characterized by high activity against Gram-positive cocci and some Gram-positive and -negative anaerobes, including Clostridium difficile. This study investigates the role of prior quinolone use in relation to patterns of susceptibility of C. difficile to moxifloxacin. Methods. Sixty-three clinical isolates of C. difficile were investigated for toxigenicity, susceptibility to moxifloxacin, and mutations in the DNA gyrase gene. The medical histories for 50 of these patients were available and used to identify previous fluoroquinolone use. Results. Thirty-three (52.4{\%}) strains showed resistance to moxifloxacin (MICs ≥ 16 mg/L). All moxifloxacin-resistant strains harbored a mutation at amino acid codon Ser-83 of gyrA. Forty-five isolates (71.4{\%}) were toxigenic; all moxifloxacin-resistant strains were in this group. Resistance to moxifloxacin was associated with prior use of fluoroquinolones (P-value 0.009, chi-square). Conclusions. Although the use of moxifloxacin to treat C. difficile-associated diarrhea is not likely to be common, these data show a relationship between antecedent fluoroquinolone use and resistance to moxifloxacin in C. difficile isolates, and raise questions regarding selection pressure for resistance placed on colonizing bacteria exposed to fluoroquinolones. Mutations in gyrA are involved in moxifloxacin resistance.",
keywords = "Clostridium difficile, Moxifloxacin, Resistance",
author = "G. Ackermann and Tang-Feldman, {Y. J.} and R. Schaumann and Henderson, {J. P.} and Rodloff, {A. C.} and Jr Silva and Cohen, {Stuart H}",
year = "2003",
month = "6",
day = "1",
doi = "10.1046/j.1469-0691.2003.00559.x",
language = "English (US)",
volume = "9",
pages = "526--530",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile

AU - Ackermann, G.

AU - Tang-Feldman, Y. J.

AU - Schaumann, R.

AU - Henderson, J. P.

AU - Rodloff, A. C.

AU - Silva, Jr

AU - Cohen, Stuart H

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective. Moxifloxacin is characterized by high activity against Gram-positive cocci and some Gram-positive and -negative anaerobes, including Clostridium difficile. This study investigates the role of prior quinolone use in relation to patterns of susceptibility of C. difficile to moxifloxacin. Methods. Sixty-three clinical isolates of C. difficile were investigated for toxigenicity, susceptibility to moxifloxacin, and mutations in the DNA gyrase gene. The medical histories for 50 of these patients were available and used to identify previous fluoroquinolone use. Results. Thirty-three (52.4%) strains showed resistance to moxifloxacin (MICs ≥ 16 mg/L). All moxifloxacin-resistant strains harbored a mutation at amino acid codon Ser-83 of gyrA. Forty-five isolates (71.4%) were toxigenic; all moxifloxacin-resistant strains were in this group. Resistance to moxifloxacin was associated with prior use of fluoroquinolones (P-value 0.009, chi-square). Conclusions. Although the use of moxifloxacin to treat C. difficile-associated diarrhea is not likely to be common, these data show a relationship between antecedent fluoroquinolone use and resistance to moxifloxacin in C. difficile isolates, and raise questions regarding selection pressure for resistance placed on colonizing bacteria exposed to fluoroquinolones. Mutations in gyrA are involved in moxifloxacin resistance.

AB - Objective. Moxifloxacin is characterized by high activity against Gram-positive cocci and some Gram-positive and -negative anaerobes, including Clostridium difficile. This study investigates the role of prior quinolone use in relation to patterns of susceptibility of C. difficile to moxifloxacin. Methods. Sixty-three clinical isolates of C. difficile were investigated for toxigenicity, susceptibility to moxifloxacin, and mutations in the DNA gyrase gene. The medical histories for 50 of these patients were available and used to identify previous fluoroquinolone use. Results. Thirty-three (52.4%) strains showed resistance to moxifloxacin (MICs ≥ 16 mg/L). All moxifloxacin-resistant strains harbored a mutation at amino acid codon Ser-83 of gyrA. Forty-five isolates (71.4%) were toxigenic; all moxifloxacin-resistant strains were in this group. Resistance to moxifloxacin was associated with prior use of fluoroquinolones (P-value 0.009, chi-square). Conclusions. Although the use of moxifloxacin to treat C. difficile-associated diarrhea is not likely to be common, these data show a relationship between antecedent fluoroquinolone use and resistance to moxifloxacin in C. difficile isolates, and raise questions regarding selection pressure for resistance placed on colonizing bacteria exposed to fluoroquinolones. Mutations in gyrA are involved in moxifloxacin resistance.

KW - Clostridium difficile

KW - Moxifloxacin

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=0038301894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038301894&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2003.00559.x

DO - 10.1046/j.1469-0691.2003.00559.x

M3 - Article

C2 - 12848728

AN - SCOPUS:0038301894

VL - 9

SP - 526

EP - 530

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 6

ER -